PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $242,000 | -90.7% | 7,931 | -76.8% | 0.00% | -100.0% |
| Q1 2022 | $2,604,000 | +1182.8% | 34,201 | +909.2% | 0.01% | – |
| Q4 2021 | $203,000 | +1.5% | 3,389 | -4.4% | 0.00% | -100.0% |
| Q3 2021 | $200,000 | -1.5% | 3,546 | +4.8% | 0.00% | 0.0% |
| Q2 2021 | $203,000 | -14.7% | 3,383 | +0.3% | 0.00% | 0.0% |
| Q1 2021 | $238,000 | +19.0% | 3,374 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $200,000 | -23.1% | 3,374 | -22.9% | 0.00% | 0.0% |
| Q3 2020 | $260,000 | +26.8% | 4,374 | +12.2% | 0.00% | 0.0% |
| Q2 2020 | $205,000 | -13.5% | 3,900 | -29.5% | 0.00% | -50.0% |
| Q4 2018 | $237,000 | -13.5% | 5,535 | -1.2% | 0.00% | 0.0% |
| Q3 2018 | $274,000 | -0.4% | 5,603 | -6.6% | 0.00% | 0.0% |
| Q4 2017 | $275,000 | +21.7% | 6,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $226,000 | +3.2% | 6,000 | +44.7% | 0.00% | +100.0% |
| Q1 2016 | $219,000 | -32.6% | 4,147 | -1.8% | 0.00% | -75.0% |
| Q4 2015 | $325,000 | – | 4,225 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |